Arch Therapeutics, Inc. — key financial figures for fiscal year 2023 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2023)

$75.7K

Net Income/Loss (FY2023)

-$7.0M

Total Assets (FY2023)

$2.0M

Total Equity (FY2023)

-$7.5M

Cash Flows from Operating Activities (FY2023)

-$3.4M

Source: Arch Therapeutics, Inc. 10-K filing (FY2023). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.